Table 3.
Promotion of indefinite organ allograft† survival in rodents by adoptive transfer of tolDC
| DC | Species | DC treatment | Additional host treatment | Route of injection (day, d) | MST | Ref |
|---|---|---|---|---|---|---|
| Donor-derived tolDC | ||||||
| MoDC | Rat | GM-CSF | TLI; ATG | iv (d14/15) | >160d | [136] |
| BMDC | Mouse | GM-CSF + IL-4 or TGFβ | Anti-CD40L mAb | iv (d −7) | >100d (40%) | [137] |
| BMDC | Mouse | Low GM-CSF | None | iv (d −7) | >100d | [77] |
| BMDC | Mouse | BM-CSF + IL-4 + NFκβ ODN + rAd CTLA4Ig | None | iv (d −7) | >100d (40%) | [90] |
| BMDC | Rat | Low GM-CSF + IL-4 | ALS | iv (d −7) | >200d§ (50%) | [138] |
| BMDC | Mouse | Low GM-CSF | Anti-CD54 mAb + CTLA4Ig | iv (d −7) | 100d | [139] |
| BMDC | Rat (kidney) | GM-CSF + IL-4 + dexamethasone | CTLA4Ig (x1) + cyclosporine | iv (d −10) | >100d | [140] |
| BMDC | Rat (liver) | GM-CSF + IL-4 | host Tregs | iv (d −7) (both tolDC and Treg) | 22d (tolDC); 30d (Treg); 42d (tolDC + Treg) vs. 8d (control) | [141] |
| Spleen DC | Mouse (skin) | Flt3L | Cyclophosphamide + T cell-depleted donor BM cells | iv (d 0) | >100d | [142] |
| BMDC | Mouse (skin) | Flt3L | CTLA4Ig + anti-CD40L; anti-NK1.1Ab | iv (d −10) | 51d (tolDC) vs. 15d (conrol) | [91] |
| Recipient-derived tolDC | ||||||
| BMDC | Rat | GM-CSF + IL-4 + donor MHC I peptide (RT1.Au) | ALS | it (d −7) | >150d | [143] |
| BMDC | Rat | GM-CSF + IL-4 + donor MHC I peptide (RT1.Au) | ALS | iv (d −7) | >200d | [82] |
| BMDC | Mouse | GM-CSF + IL-4 + RAPA + donor cell lysate | None | iv (X3) (d −10, −3, 0) | >100d | [61] |
| BMDC | Rat | GM-CSF + IL-4 | LF 15–0195* | iv | >100d | [83] |
| BMDC | Mouse | GM-CSF + IL-4 | NFκβ ODN + donor-derived lysate | iv | >100d (33%) | [144] |
| BMDC | Rat | Low GM-CSF + IL-4 | None | iv | >100d (20%) | [84] |
†
Heart allografts unless otherwise specified;
*
Deoxyspergaulin derivative;
ALS: anti-lymphocyte serum; ATG: anti-thymocyte globulin; BMDC: bone marrow-derived dendritic cells; Flt3L: fms-like tyrosine kinase 3 ligand; i.t: intra-thymic; iv: intravenous; MoDC: monocyte-derived DC; MST: mean survival time; ODN: oligodeoxyribonucleotides; rAd: recombinant adenovirus; RAPA: rapamycin; TLI: total lymphoid irradiation; Tregs: regulatory T cells